Dr. George Demetri

Liquid Biopsy Holds Promise for Precision Medicine

In a recent release from the Translational Genomics Research Institute (TGen), it was reported that researchers have discovered that by analyzing circulating tumor DNA (ctDNA) through liquid biopsy that a patient's cancer can be tracked [...]

By |2018-10-30T11:23:07-04:00December 29th, 2015|News, Research|

Importance of Therapeutic Drug Monitoring for Targeted Therapies

As personalized medicine has become an accepted paradigm, it may be time for oncologists to examine personalized dose levels.In a recent article from Cancer World, the author explores the value of therapeutic drug monitoring for [...]

By |2019-04-08T10:18:30-04:00May 1st, 2015|Drug Treatment, News|

Results from collaborative trial announced at ASCO

At the recent American Society of American Oncology Meeting (ASCO), Dr. George Demetri, Director of the Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, presented results from a collaborative trial that indicates in [...]

By |2019-09-20T15:24:55-04:00June 13th, 2014|Clinical Trials, News|
Go to Top